Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Auditor change
Director departure
MALACHITE INNOVATIONS, INC. (VBIO) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/01/2023 8-K Quarterly results
05/31/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "MALACHITE INNOVATIONS REPORTS FIRST QUARTER 2023 RESULTS"
04/13/2023 8-K Quarterly results
09/22/2022 8-K/A Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Consent of Independent Registered Public Accounting Firm",
"Financial Statements Page Independent Auditor’ s Report F-2 Balance Sheets as of December 31, 2021 and December 31, 2020 F-3 Statements of Operations for the years ended December 31, 2021 and December 31, 2020 F-4 Statements of Stockholders’ Equity for the years ended December 31, 2021 and December 31, 2020 F-5 Statements of Cash Flows for the years ended December 31, 2021 and December 31, 2020 F-6 Notes to Financial Statements F-7 F- 1 Independent Auditor’ s Report To the Shareholders of Range Environmental Resources, Inc.",
"Malachite Innovations, Inc. Pro Forma Consolidated Balance Sheet Malachite Innovations Inc. Range Environmental Resources, Inc. Pro Forma Adjustments Pro Forma Total Current assets Cash $ 44,162 $ 87,058 $ - $ 131,220 Accounts receivable, net - 853,311 - 853,311 Prepaid expenses 884 - - 884 Total current assets 45,046 940,369 - 985,415 Property and equipment, net of accumulated depreciation - 400,886 182,114 583,000 Deposits 8,892 - - 8,892 Operating lease asset - 130,630 - 130,630 Goodwill - - 779,165 779,165 Total Assets 53,938 1,471,885 961,279 2,487,102 Current liabilities Accounts payable and accrued liabilities 133,553 286,998 - 420,551 Current portion of long-term debt - 49,625 - 49,625 Line of Credit 750,000 - - 750,000 Total current liabilities 883,553 336,623 - 1,220,176 Long-ter..."
08/29/2022 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "FORM OF WARRANT NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED , AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES. COMMON STOCK..."
08/16/2022 8-K Quarterly results
07/15/2022 8-K Quarterly results
05/13/2022 8-K Quarterly results
03/15/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "MALACHITE INNOVATIONS ANNOUNCES SIGNED LETTER OF INTENT WITH RANGE ENVIRONMENTAL RESOURCES, INC. 15 MAR 2022 / PRESS RELEASE",
"LETTER OF INTENT"
03/09/2022 8-K Quarterly results
12/28/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "MALACHITE INNOVATIONS ANNOUNCES TWO GRANTED U.S. PATENTS AND NEW PCT PATENT FILING CLEVELAND, OHIO – – MALACHITE INNOVATIONS, INC. announces that its wholly-owned drug development subsidiary, Graphium Biosciences, Inc., has been granted two patents by the U.S. Patent and Trademark Office for its cannabinoid glycoside prodrug, and has filed a new patent under the Patent Cooperation Treaty for its novel manufacturing process used to produce its proprietary cannabinoid glycosides. The Company's new patent application was filed with the USPTO and preserves our right to seek patent protection in 153 foreign nations that are signatories of the PCT. Granted: Cannabinoid Glycoside Prodrugs and Methods of Synthesis Graphium Biosciences has been granted a patent by the USPTO for its “Cannabinoid Gly..."
10/12/2021 8-K Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other E...
Docs: "PLAN OF MERGER THIS PLAN OF MERGER is adopted, made and entered into as of September 30, 2021 by Vitality Biopharma, Inc., a Nevada corporation , in accordance with Section 92A.180 of the Nevada Revised Statutes . 1. Parent and Subsidiary . Malachite Innovations, Inc., a Nevada corporation , is a wholly-owned subsidiary of Parent. 2. Merger . Merger Sub shall be merged with and into Parent at the Effective Time . Following the Effective Time, the separate existence of Merger Sub shall cease, and Parent shall continue as the surviving corporation surviving the Merger and its name shall be changed to “Malachite Innovations, Inc.” . The effects and consequences of the Merger shall be as set forth in this Plan of Merger, the Articles of Merger filed with the Secretary of State of the State of ...",
"VITALITY BIOPHARMA ADOPTS NEW NAME – MALACHITE INNOVATIONS, INC."
09/02/2021 8-K Quarterly results
08/20/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "VITALITY BIOPHARMA ENTERS INTO $5 MILLION EQUITY LINE FINANCING RELATIONSHIP WITH INSTITUTIONAL INVESTOR"
08/12/2021 8-K Submission of Matters to a Vote of Security Holders
08/10/2021 8-K Other Events, Financial Statements and Exhibits
Docs: "FDA GRANTS VITALITY BIOPHARMA ORPHAN DRUG DESIGNATION FOR VBX-100 PRODRUG"
06/22/2021 8-K Quarterly results
06/16/2021 8-K Quarterly results
03/12/2021 8-K Quarterly results
09/25/2020 8-K Quarterly results
05/14/2020 8-K Quarterly results
04/27/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/01/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/21/2019 8-K Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets
05/14/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Separation agreement and Release between the Company and Mr. Robert Brooke",
"Third Amendment to the Vitality Biopharma, Inc. 2012 Stock Incentive Plan",
"Notice Regarding Forward-Looking Statements"
04/25/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Vitality Biopharma"
01/24/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Vitality Biopharma"
01/22/2019 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Amendment to Securities Purchase Agreement"
01/07/2019 8-K/A Financial Statements and Exhibits
Docs: "Consent of Independent Registered Public Accounting Firm",
"Audited financial statements of The Control Center, Inc. as of September 30, 2018 and 2017 and for the years then ended and accompanying notes",
"Unaudited Pro Forma Condensed Consolidated Balance Sheet of Vitality Biopharma, Inc. and The Control Center, as of September 30, 2018, and Unaudited Pro Forma Combined Condensed Statements of Operations of Vitality Biopharma, Inc. and The Control Center, Inc. for the year ended March 31, 2018 and for the six-month period ended September 30, 2018"
11/21/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Vitality Biopharma [email protected] 1-530-231-7800 www.vitality.bio Notice Regarding Forward-Looking Statements This news release contains “forward-looking statements” as that term is defined in Section 27 of the United States Securities Act of 1933, as amended and Section 21 of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies, use of proceeds from $8.5M financing, continuing SEC private investigation, resumption of trading of the Company’ s common stock on the OTCQB or na..."
11/15/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Form of Indemnification Agreement"
10/26/2018 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Executive Employment Agreement, between Vitality Healthtech and Dr. Arif Karim"
10/23/2018 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity ...
Docs: "Form of Common Stock Purchase Warrant",
"Securities Purchase Agreement, by and among Vitality Biopharma, Inc., and the Purchasers listed on the signature pages thereto",
"Securities Exchange Agreement, by and among Vitality Biopharma, Inc., and the Shareholders listed on the signature pages thereto",
"Form of Lockup Agreement",
"Share Purchase Agreement, by and between Summit Healthtech, Inc. and Dr. Reef Karim",
"Share Restriction Agreement, by and among Summit Healthtech, Inc., the Control Center, Inc. and Dr. Reef Karim"
09/04/2018 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Form of Common Stock Purchase Warrant",
"Securities Purchase Agreement, by and among Vitality Biopharma, Inc., and the Purchaser listed on the signature pages thereto"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy